Table 3.
Characteristics of patients and lesions after propensity score matching
| Variable | Cilostazol (n = 102) | Control (n = 102) | P value |
|---|---|---|---|
| Number of patients | 54 | 52 | |
| Men (%) | 66.7 | 71.2 | 0.61 |
| Age (years) | 66 ± 10 | 65 ± 8 | 0.56 |
| Duration of HD (years) | 5.6 ± 6.8 | 4.9 ± 5.1 | 0.48 |
| Diabetes (%) | 59.3 | 55.8 | 0.71 |
| Hypertension (%) | 62.9 | 63.5 | 0.89 |
| Hyperlipidemia (%) | 22.2 | 26.9 | 0.61 |
| Smoking (%) | 22.2 | 25.0 | 0.65 |
| Coronary artery disease (%) | 50.0 | 36.5 | 0.14 |
| Past history of stroke (%) | 5.6 | 13.5 | 0.16 |
| Indication for PTA (%) | 0.67 | ||
| Intermittent claudication | 51.8 | 46.2 | |
| Rest pain | 27.8 | 26.9 | |
| Ulcer/gangrene | 20.4 | 26.9 | |
| Preoperative ABPI | 0.67 ± 0.26 | 0.62 ± 0.35 | 0.31 |
| Lesion location (%) | |||
| Iliac | 32.4 | 26.5 | 0.36 |
| Femoropopliteal | 67.6 | 73.5 | |
| TASC classification (%) | 0.92 | ||
| Type A + B | 64.4 | 63.7 | |
| Type C + D | 35.6 | 36.3 | |
| Stent use (%) | 55.9 | 52.9 | 0.67 |
| Medication (%) | |||
| ACE inhibitors | 18.5 | 26.9 | 0.30 |
| A-II receptor blockers | 25.9 | 32.7 | 0.44 |
| β-blockers | 20.4 | 15.4 | 0.50 |
| Calcium antagonists | 68.5 | 63.5 | 0.58 |
| Statins | 16.7 | 9.6 | 0.28 |
| Warfarin | 7.4 | 11.5 | 0.46 |
| Ticlopidine | 38.9 | 44.2 | 0.57 |
| Sarpogrelate | 5.6 | 36.5 | <0.0001 |
PTA, percutaneous transluminal angioplasty.